AbbVie (ABBV) Long-Term Investments (2012 - 2026)

AbbVie (ABBV) has 15 years of Long-Term Investments data on file, last reported at $268.0 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $268.0 million, down 6.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $268.0 million (down 6.62% YoY), and the FY2025 annual result was $268.0 million, down 3.94% from the prior year.
• Long-Term Investments steadied at $268.0 million in Q1 2026 per ABBV's latest filing, from $268.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $310.0 million in Q2 2025 and troughed at $235.0 million in Q3 2022.
• A 5-year average of $273.6 million and a median of $272.0 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments retreated 14.75% in 2022, then grew 26.14% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $241.0 million in 2022, then climbed by 26.14% to $304.0 million in 2023, then decreased by 8.22% to $279.0 million in 2024, then dropped by 3.94% to $268.0 million in 2025, then changed by 0.0% to $268.0 million in 2026.
• Business Quant data shows ABBV's Long-Term Investments at $268.0 million in Q1 2026, $268.0 million in Q4 2025, and $291.0 million in Q3 2025.